



(51) International Patent Classification:

C12Q 1/6886 (2018.01) G06F 19/00 (2018.01)
C12Q 1/6883 (2018.01) G01N 33/48 (2006.01)

(21) International Application Number:

PCT/US2020/026269

(22) International Filing Date:

01 April 2020 (01.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/828,224 02 April 2019 (02.04.2019) US
62/961,517 15 January 2020 (15.01.2020) US

(71) Applicant: **GRAIL, INC.** [US/US]; 1525 O'Brien Drive,
Menlo Park, California 94025 (US).

(72) Inventors: **LO, Yuk-Ming Dennis**; 4/F, 7 King Tak Street,
Homantin, Kowloon, Hong Kong (CN). **CHIU, Rossa Wai
Kwun**; House 31, Double Haven, 52 Ma Lok Path, Shatin,
New Territories, Hong Kong (CN). **CHAN, Kwan Chee**;
16B, Eastview, 3 Cox's Road, Jordan, Kowloon, Hong

Kong (CN). **JIANG, Peiyong**; Flat 16, 10th Floor, Block
C, Fook Lam House, Nos. 62-66 (No. 66) Siu Lek Yuen
Road, Shatin, New Territories, Hong Kong (CN). **LAM,
Wai Kei**; Flat B, 3/F, Block 14 Beacon Heights, 14 Lung
Ping Road, Kowloon, Hong Kong (CN). **Ji, Lu**; Room 503,
Li Ka Shing Medical Sciences Building, The Chinese Uni-
versity of Hong Kong, Shatin, New Territories, Hong Kong
(CN).

(74) Agent: **HUANG, Wei**; WILSON SONSINI GOODRICH
& ROSATI, 650 Page Mill Road, Palo Alto, California
94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: STRATIFICATION OF RISK OF VIRUS ASSOCIATED CANCERS

Illustrative example for variable interval of NPC screening based on plasma EBV DNA status




FIG. 2

(57) Abstract: Provided herein are methods and systems for stratifying risk for a subject to develop a pathogen-associated disorder based on analysis of cell-free nucleic acid molecules from a biological sample of the subject. In various examples, screening frequency is determined based on the risk analysis. Also provided herein are methods and systems for analyzing variant patterns of a pathogen genome in cell-free nucleic acid molecules.

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))